实用药物与临床
實用藥物與臨床
실용약물여림상
PRACTICAL PHARMACY AND CLINICAL REMEDIES
2014年
10期
1349-1352
,共4页
布地奈德%儿童%呼吸道合胞病毒%喘息发作%炎症因子%T细胞亚群
佈地奈德%兒童%呼吸道閤胞病毒%喘息髮作%炎癥因子%T細胞亞群
포지내덕%인동%호흡도합포병독%천식발작%염증인자%T세포아군
Budesonide%Children%Respiratory syncytial virus%Wheezing%Inflammatory factor%T lymphocytes subsets
目的观察和分析布地奈德治疗儿童呼吸道合胞病毒( RSV)感染相关喘息的疗效及其对血清炎症介质水平的影响。方法选取200例RSV感染相关首次喘息发作的患儿,随机分为观察组和对照组,每组100例。两组患儿均给予基础对症治疗,对照组患儿在此基础上应用万托林雾化液吸入治疗,观察组患儿在对照组疗法基础上联合应用布地奈德混悬液吸入治疗。对两组患儿的呼吸改善时间、喘息缓解时间和住院时间以及治疗前后血清白细胞介素-4(IL-4)、IL-6、IL-12、C反应蛋白(CRP)、IgE水平和外周血T淋巴细胞亚群情况进行观察和检测,并对患儿出院后6个月和1年内的喘息发作情况和发生哮喘情况进行随访和观察。结果观察组患儿的呼吸改善时间、喘息改善时间、住院时间均显著短于对照组( P<0.05);治疗后,两组患儿的血清IL-4、IL-6、CRP、IgE水平和CD8+T细胞比例较治疗前显著下降( P<0.05),而血清IL-12水平和CD3+T细胞比例、CD4+T细胞比例、CD4+/CD8+T细胞比值较治疗前显著上升( P<0.05),且观察组患者上述指标的变化幅度显著大于对照组(P<0.05);观察组患儿于出院6个月内和1年内喘息发作的比例均显著低于对照组(P<0.05)。结论应用布地奈德治疗儿童RSV感染相关喘息的疗效显著,可更快速地缓解患儿症状,显著改善患儿炎症介质水平,降低喘息复发几率。
目的觀察和分析佈地奈德治療兒童呼吸道閤胞病毒( RSV)感染相關喘息的療效及其對血清炎癥介質水平的影響。方法選取200例RSV感染相關首次喘息髮作的患兒,隨機分為觀察組和對照組,每組100例。兩組患兒均給予基礎對癥治療,對照組患兒在此基礎上應用萬託林霧化液吸入治療,觀察組患兒在對照組療法基礎上聯閤應用佈地奈德混懸液吸入治療。對兩組患兒的呼吸改善時間、喘息緩解時間和住院時間以及治療前後血清白細胞介素-4(IL-4)、IL-6、IL-12、C反應蛋白(CRP)、IgE水平和外週血T淋巴細胞亞群情況進行觀察和檢測,併對患兒齣院後6箇月和1年內的喘息髮作情況和髮生哮喘情況進行隨訪和觀察。結果觀察組患兒的呼吸改善時間、喘息改善時間、住院時間均顯著短于對照組( P<0.05);治療後,兩組患兒的血清IL-4、IL-6、CRP、IgE水平和CD8+T細胞比例較治療前顯著下降( P<0.05),而血清IL-12水平和CD3+T細胞比例、CD4+T細胞比例、CD4+/CD8+T細胞比值較治療前顯著上升( P<0.05),且觀察組患者上述指標的變化幅度顯著大于對照組(P<0.05);觀察組患兒于齣院6箇月內和1年內喘息髮作的比例均顯著低于對照組(P<0.05)。結論應用佈地奈德治療兒童RSV感染相關喘息的療效顯著,可更快速地緩解患兒癥狀,顯著改善患兒炎癥介質水平,降低喘息複髮幾率。
목적관찰화분석포지내덕치료인동호흡도합포병독( RSV)감염상관천식적료효급기대혈청염증개질수평적영향。방법선취200례RSV감염상관수차천식발작적환인,수궤분위관찰조화대조조,매조100례。량조환인균급여기출대증치료,대조조환인재차기출상응용만탁림무화액흡입치료,관찰조환인재대조조요법기출상연합응용포지내덕혼현액흡입치료。대량조환인적호흡개선시간、천식완해시간화주원시간이급치료전후혈청백세포개소-4(IL-4)、IL-6、IL-12、C반응단백(CRP)、IgE수평화외주혈T림파세포아군정황진행관찰화검측,병대환인출원후6개월화1년내적천식발작정황화발생효천정황진행수방화관찰。결과관찰조환인적호흡개선시간、천식개선시간、주원시간균현저단우대조조( P<0.05);치료후,량조환인적혈청IL-4、IL-6、CRP、IgE수평화CD8+T세포비례교치료전현저하강( P<0.05),이혈청IL-12수평화CD3+T세포비례、CD4+T세포비례、CD4+/CD8+T세포비치교치료전현저상승( P<0.05),차관찰조환자상술지표적변화폭도현저대우대조조(P<0.05);관찰조환인우출원6개월내화1년내천식발작적비례균현저저우대조조(P<0.05)。결론응용포지내덕치료인동RSV감염상관천식적료효현저,가경쾌속지완해환인증상,현저개선환인염증개질수평,강저천식복발궤솔。
Objective To observe and analyze the curative effects of budesonide treatment for the children with respiratory syncytial virus ( RSV) infection associated wheezing and its influence on the serum inflammatory me-diators levels.Methods 200 patients with the first RSV infection associated wheezing were selected and randomly di-vided into observation group and control group.All the patients in the two groups were treated with the basic treatment. Control group ( n=100) was added with liquid aerosol ventolin inhalation treatment,while the observation group ( n=100 ) was treated with budesonide inhalation treatment on the basis of control group.The respiratory improvement time, wheezing remission time, hospitalization time and the serum interleukin-4 ( IL-4), IL-6, IL-12, C reactive protein ( CRP) ,IgE levels and T lymphocytes subsets in the peripheral blood of the children in the two groups were observed and detected before and after treatment.Meanwhile,the patients were followed-up and the wheezing recurrence rates, asthma occurrence in 6 months and 1 year after the discharged day were observed.Results The respiratory improve-ment time,wheezing remission time and the hospitalization time of observation group were significantly shorter than those of control group (P<0.05).After treatment,the serum IL-4,IL-6,CRP,IgE levels and CD8 +T lymphocyte pro-portion of the two groups decreased significantly (P<0.05),while the serum IL-12 level,CD3 +T lymphocyte propor-tion,CD4 +T lymphocyte proportion,the ratio of CD4 +/CD8 +T lymphocyte increased significantly (P <0.05),and there were significant differences in the above indexes between the 2 groups ( P<0.05 ) .The wheezing recurrence rati-os in the 6 months and 1 year after the discharged day of observation group were significantly lower than those of con-trol group ( P<0.05 ) .Conclusion The curative effects of budesonide in the treatment of the children with RSV in-fection associated wheezing is significant.The therapy can alleviate the symptoms more quickly,improve the levels of inflammatory mediators and reduce the occurrence of recurrence.